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Summary
 Human T-cell lymphotropic virus type I (HTLV-I), a 
causative virus of adult T-cell leukemia (ATL), transmits 
through both horizontal and vertical pathways. Since ATL 
develops in only carriers infected early in life, vertical 
transmission cycle is the most important target of interven-
tion for the purpose of the prevention of ATL. 
Epidemiological studies in an endemic area, Nagasaki, 
Japan, and animal experiments identified milk-borne mater-
nal transmission as the major vertical pathway. The 
prefecture-wide intervention in Nagasaki since 1987 has re-
vealed that the refraining from breast-feeding by carrier 
mothers can prevent about 85% of maternal HTLV-I trans-
mission. Pathways for the remaining 15% await for eluci-
dation. However, our studies argued against the possibili-
ties of intrauterine transmission and infection via saliva. 
Perinatal transmission remains to be evaluated as the alter-
native pathway. At present, refraining from breast-feeding 
is the most effective measure to break the cycle of mater-
nal HTLV-I transmission in endemic areas. It is estimated 
that the intervention in Nagasaki for the past 10 years has 
prevented 1,000 maternal transmission and 50 future ATL 
cases. I am reasonably confident that incidence of ATL in 
Nagasaki will decline to the national average level over 
the next few generation if the intervention program stays 
alive.
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Introduction
Human T-cell lymphotropic virus type I (HTLV-I), a
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human retrovirus, is a causative agent of adult T-cell 
leukemia (ATL) 1.21 as well as HTLV-I-associated 
myelopathy/tropical spastic paraparesis (HAM/ 
TSP)3'4) and some other inflammatory disorders of 
various organs',-'). HTLV-I is endemic in the specific 
geographic areas in the world, such as Japan, 
Caribbean basin, South America, and Africa'-'2. In 
Japan, the virus is distributed in southwestern coast'), 
including Nagasaki Prefecture located in the western-
most part of mainland Japan. Carriers of HTLV-I in 
Nagasaki have been estimated to be about 60,000 
(4%) in a population of 1.5 million 13). The prevalence 
of HTLV-I carriers increases with age: the average 
prevalence among those older than 40 years is about 
10%"). Approximately 4-5% of carriers are presumed 
to develop ATL after a long latency. The annual inci-
dence of ATL in Nagasaki is about 100 cases, which 
corresponds to 0.5% of total death in the prefec-
ture","). ATL is a fatal disease due to its resistance 
against a conventional chemotherapy, high incidences 
of hypercalcemia, and leukemic cell infiltration in vari-
ous organs. Unfortunately, there is no measure to pre-
vent the development of ATL among carriers at pre-
sent. Breaking the cycle of HTLV-I transmission has 
thus been urgently needed in the endemic areas. 
 HTLV-I infects mainly CD4+ T cells in vivo and the 
proviral genome is integrated in chromosomal DNA of 
the infected cells. The virus transmits through both 
horizontal and vertical pathways. Since HTLV-I infects 
in only cell-to-cell manner"), the sources of infection 
are required to contain a significant number of in-
fected T cells. The major routes of horizontal transmis-
sion are through blood transfusion and sexual contact. 
About a half of recipients transfused with carriers' 
whole blood were shown to be infected"'. In Japan in-
cluding Nagasaki, however, the screening of donated 
blood for antibodies to HTLV-I since 1985 has reduced 
the blood-borne infection to the negligible level"). 
Sexual transmission via seminal fluids was proved by 
the demonstration of HTLV-I-infected cells in carriers' 
seminal fluids"' and by the epidemiological data
showing that most of the wives of carrier husbands 
were infected in a Japanese cohort"'. However, one-
way male-to-female transmission is not always the case 
in other population. Female-to-male transmission is also 
frequent in countries where other sexually transmitted 
diseases (STD), including human immunodeficiency 
virus (HIV) infection, are common"'. These diseases 
themselves, resulting immunosuppression, and/or pro-
miscuous sexual behaviour of STD patients may in-
crease vulnerability to sexual HTLV-I infection. Sexual 
transmission, together with maternal transmission de-
tailed in the following sections, are likely to have re-
sulted in the familial clustering of carriers, a character-
istic feature of HTLV-I endemicity. 
 HTLV-I exerts its pathogenicity in only a minor 
population of carriers. Although pathogenic mecha-
nisms are not well understood, epidemiological studies 
have identified some risk factors for some HTLV-I-
associated diseases. For instance, HTLV-I infection 
through blood transfusion was shown to be a risk fac-
tor for HAM/TSP2". In contrast, ATL seems to de-
velop in only carriers infected early in life","', since 
there is no confirmed ATL cases among carriers in-
fected through blood-borne or sexual transmission 
to date. This may be due to the multi-step 
leukemogenesis of ATL which requires a long latency, 
usually 40-50 years after infection24'. Maternal infection 
cycle is thus the most important target of intervention 
for the purpose of the prevention of ATL. In this re-
view article, I introduce the studies conducted at 
Nagasaki University School of Medicine for last 15 
years regarding the identification of breast milk as the 
major source of maternal HTLV-I transmission,. the in-
tervention of the milk-borne transmission in Nagasaki, 
and the attempts to identify alternative maternal path-
ways.
Maternal transmission of HTLV-I via 
breast milk
 The presence of mother-to-child pathways of HTLV-I 
transmission was first indicated by the epidemiological 
studies in an endemic area, Nagasaki, in 1985. Hino et 
al."' demonstrated that HTLV-I seroprevalence among 
children born to carrier mothers (22%) was signifi-
cantly higher than that of age-matched general popula-
tion (about 1%). Moreover, more than 90% of carrier 
children's mothers were shown to be infected"). This 
close association between the infected mother and 
child strongly suggested the presence of maternal 
transmission pathways. Maternal transmission may 
occur through intrauterine, perinatal, and postnatal 
routes. HTLV-I infection through blood transfusion
usually results in seroconversion within a few months 
after the transfusion"). In contrast, most of carrier chil-
dren seroconvert betweeen 6 and 12 months of age"'. 
This delayed seroconversion in carrier children raised 
the idea that the postnatal pathway is the most prob-
able candidate for maternal HTLV-I transmission. 
 Since HTLV-I transmission requires infected T cells, 
we considered the breast milk, containing 106 cells/ml 
in average, as the most likely source of postnatal 
transmission. By the short-term culture and subse-
quent indirect immunofluorescence assay, about 0.1% 
of cells in the breast milk of carrier mothers were 
found to be infected25.26'. If a carrier mother gives her 
baby 500 ml of breast milk every day for 200 days, 
108 infected cells are presumed to be transferred to the 
baby before weaning. 
 Hino et al."' then retrospectively asked 83 carrier 
mothers, including 17 with infected children, for his-
tory of breast-feeding. All of the infected children ap-
peared to be breast-fed, and the carrier rate among 
breast-fed children was 17/73 (23%). In contrast, 
none of 10 never-breast-fed children was infected. 
 In order to examine whether oral inoculation of in-
fected cells has a potential to transmit HTLV-I, animal 
experiments were conducted using the common mar-
moset (Callithrix jacchus) which lacked simian T-cell 
lymphotropic virus (STLV) crossreacting with HTLV-
I. First, Yamanouchi et al.26' inoculated cultured periph-
eral blood mononuclear cells (PBMC) of ATL patients 
(7.8x 107 cells in total by 6 inoculations) into the oral 
cavity of marmosets using a syringe without a needle 
to avoid the mucosal injury. In one of the two inocu-
lated marmosets, seroconversion occurred 2.3 months 
after the first inoculation. HTLV-I infection in the 
seroconverted marmoset was confirmed by the pres-
ence of infected T cells in the PBMC after the short-
term cell cultured'. Next, fresh breast milk samples ob-
tained from carrier mothers were orally inoculated to 
a marmoset, 200m1 in total by 23 inoculations. The 
marmoset again revealed seroconversion 2.5 months 
after the first inoculation and was confirmed to be in-
fected by the detection of infected T cells28'. 
 These findings strongly suggested that breast milk 
is the major source of maternal HTLV-I transmission. 
Presumably, infected T cells in the milk migrate to the 
lymphatic tissues in the oral cavity or the intestine, 
and transmit the virus to children's T cells in cell-to-
cell manner.
Intervention of milk-borne HTLV-I 
transmission in Nagasaki
In an attempt to break the cycle of mother-to-child
transmission, the intervention program, namely ATL 
Prevention Program (APP), in Nagasaki Prefecture 
started in 1987 in collaboration with the prefectural 
government, Nagasaki Medical Association, Nagasaki 
University School of Medicine, and Nagasaki Central 
Hospital","'. The APP has involved the screening out 
of HTLV-1 carriers from among pregnant women, the 
refraining from breast-feeding by carrier mothers, and 
the following up of their children. After obtaining the 
informed consent, pregnant females have been 
screened for serum anti-HTLV-I antibodies at the end 
of the second trimester. Carriers were notified the posi-
tive results and advised to refrain from breast-feeding 
by obstetricians. The children born to the carrier 
mothers have been followed up serologically at 0.5, 1.0, 
1.5, 2.0, and 3.0 years of age by pediatricians in the se-
lected hospitals. All the carrier mothers and their chil-
dren were coded, and they were interviewed for their 
feeding methods (bootle feeding or breast feeding and 
its period) prospectively and/or retrospectively. 
 So far, 124,387 pregnant women in the prefecture 
have attended the program for 10 years since its start 
(1988-1997). Based on the annual number of total 
birhs in the prefecture, the attending rate is estimated 
to be more than 70%. Among them 5,699 women 
(4.3%) were found to be infected. The carrier rate has 
recently been decreasing from 4.4% in average during 
1988-1991 to 3.1% in 1996 and 2.5% in 1997. This de-
cline is presumably due to the cohort effect, however, 
demographic, social or behavioural factors involved in 
this remains to be elucidated. 
 More than 90% of the carrier mothers agreed to re-
frain from breastfeeding. According to a report by the 
study group of APP in 1998, their prospective studies 
indicated that the incidence of transmission among 
bottle-fed children, 2.7%, was about 1/6 of that 
among breast-fed children, 16.9%. The results finally
confirmed breast milk as the major source 
of maternal HTLV-I transmission, and indi-
cated that refraining from breastfeeding by 
carrier mothers is the most effective meas-
ure to prevent the transmission. It is esti-
mated that the intervention for the past 10 
years has prevented 1,000 maternal trans-
mission and 50 future ATL cases.
children were infected despite bottle-feeding, suggest-
ing the presence of alternative maternal pathways 
other than via breast milk. 
 Intrauterine transmission was thought to be the 
most possible candidate for the alternative pathway. 
Using a highly sensitive nested PCR capable of detect-
ing a single molecule of the HTLV-I provirus, Kawase 
et al. screened 717 umbilical cord blood samples from 
babies born to carrier mothers. Eighteen samples 
(2.5%) gave positive results"). This raised the possibil-
ity that these children were infected in utero. We then 
followed up 7 children whose cord blood was PCR-
positive, up to between 24 and 48 months after birth. 
Surprisingly, none showed serological evidence of 
HTLV-1 infection (Table 1)3". Antibodies to HTLV-1 
detected in the sera of three 6-month-old babies were 
considered to be maternal. Maternal antibodies disap-
peared thereafter and the children older than 12 
months were exclusively seronegative. The HTLV-1 
proviral DNA in PBMC was also examined at least 
once for all the children but one by the nested PCR 
for both gag and pX regions of the HTLV-1 genome. 
All the results of PCR were negative. Therefore, the 
presence of HTLV-I in the cord blood is not a hall-
mark of intrauterine infection. HTLV-I detected in the 
cord blood was presumably derived from migrated ma-
ternal cells and excluded from the circulation after 
birth. Infected cells in the fetal and baby's circulation 
seemed to be no longer infectious. Maternal antibodies 
to HTLV-I in the circulation during pregnancy and for 
several months postpartum might prevent the HTLV-I 
transmission. 
 Next, to determine whether the approximately 3 % of 
bottle-fed children of carrier mothers who were in-
fected with HTLV-1 were infected in utero, we retro-
spectively examined the presence of HTLV-1 proviral 
DNA in frozen stocks of their cord blood (Table 2).
Intrauterine transmission of HTLV-I is un-
likely
 Although the intervention has dramati-
cally reduced the frequency of maternal 
transmission, about 3 % of carrier mothers'
Table 1. Follow-up of children whose umbilical cord blood samples 
were positive for HTLV-I proviral DNA.
     Cord Blood Follow-Up (m., months) 
Cases PCR Nutrition Serum Anti-HTLV-1 Antibody 
     gag pX 6m. 12m. 18m. 24m. 36m. 48m. 
  1 + + Formula - - - -
                                                 (PCR-)
 2 + + Formula + - - - -
                             (PCR-) (PCR-)
 3 + + Formula - -
                                     (PCR-) 
 4 + + Formula - - - -
 5 + + Formula + - (PCR-) - -
                 (PCR-) - 6 
+ + Formula + (PCR-) - -
 7 + + Formula -
                                    (PCR-)
 8 + + Breast + -
Table 2. Absence of HTLV-I proviral DNA in umbilical cord 
blood samples of newborns who were formula (bottle)-fed and 
later confirmed to be infected with HTLV-I.
     Cord Blood Follow-Up (m., months) 
Cases PCR Nutrition Serum Anti-HTLV-1 Antibody 
     gag pX 6m. 12m. 18m. 24m. 36m. 
  1 - - Formula + + 
 2 - - Formula - + + 
 3 - - Formula + + + + + 
 4 Formula + + + 
 5 - - Formula + + + + 
                        (PCR-) 
 6 Formula + + 
                                     (PCR-) 
 7 - - Formula - + + + 
 8 - - Formula - + 
 9 Formula - +
All of 9 tested children were bottle-fed and 
seropositive at the age of 12 months. Three and 4 of 
them continued to be seropositive up to 36 and 24 
months, respectively. Although data beyond 12 months 
were unavailable for the remaining 2 children, 
seroconversion was evident in both between 6 and 12 
months after birth. DNA (1 ,o g ) isolated from each 
of the cord blood samples was analyzed by the nested 
PCR, with negative results for both the gag and pX re-
gions"'. The nested PCR was capable of amplifying a 
single molecule of HTLV-1 proviral DNA"'. Since l p 
g of cellular DNA was equivalent to almost 2 x 106 
cells, the tested cord blood samples contained no, or, if 
present, less than 0.0005%, HTLV-1-infected cells. This 
finding strongly argued against intrauterine infection 
in these children.
Evaluation of saliva as an alternative source for 
postnatal maternal HTLV-I transmission
 to-cell transmission of HTLV-I in vitro, as examined 
 by syncytium inhibition assay. The natural inhibi-
 tory activity in saliva of a seronegative volunteer 
 was heat-sensitive and ultrafiltration recovered most 
 of the activity into the fraction of macromolecules 
 with a molecular weight of more than 100 
 kilodaltons (Table 3)32'. In addition to this natural 
 activity, saliva of HTLV-I-infected individuals was 
 shown to contain IgG molecules capable of neutraliz-
 ing the syncytium formation 311 . These results 
 strongly suggested that HTLV-I-infected cells in the 
 carriers' saliva, which contains neutralizing antibod-
 ies in addition to the natural activity inhibiting cell-
 to-cell viral infection, barely transmit the virus. 
 Moreover, the infected cell number of saliva poten-
 tially transferred from mothers to children are pre-
 sumed to be much smaller than that of breast milk. 
 As described above, transfer of a huge number of in-
fected cells, about 10$ cells, through breast-feeding re-
sults in the transmission rate, as high as 20-30%. We 
thus concluded that transmission of HTLV-I through 
the saliva would be rare, if at all, although well-
controlled epidemiological studies are needed to con-
firm the conclusion.
Table 3. Characteristics of HTLV-I inhibitory activity 
in saliva
     Treatment IC50 Relative inhibitory                        (l
og2)a activity (%) 
None 5.5 100 
Heating, 561C, 30 min 2.9 16 
Centricon 100 (mol wt)' 
 Filtrate (<100,000) 1.2 5 
 Retentate (>100,000) >6.0 >141
a The concentration allowing 50% inhibition of the number of syncytia 
b molecular weight (dalton)
 Yamamoto et al .31) evaluated saliva as an alternative 
source of postnatal transmission because of the follow-
ing reasons. (i) Saliva contains a significant number 
of cells including lymphocytes. (ii) It can be trans-
ferred from mothers to children by kissing or sharing 
tableware. In particular, it is a Japanese custom for 
mothers to give food chewed by themselves to their 
children during the weaning period. They used PCR to 
detect and quantify the HTLV-I provirus in saliva 
samples of 18 carrier mothers and 10 HAM/TSP pa-
tients. The provirus was detected in 60 and 90%, re-
spectively, of the samples, with estimated copy num-
bers in the range of 10-104/ml32'. However, the saliva, 
regardless of the presence or absence of antibodies to 
the virus, showed a strong tendency to inhibit the cell-
Conclusion and perspective
 Alternative pathways of maternal HTLV-I transmis-
sion other than via breast milk remain to be identified. 
Our studies did not support the possibilities of intrau-
terine transmission and infection via saliva. Among 
maternal pathways, perinatal transmission has yet to 
be evaluated. However, Sawada et al. reported the de-
tection of HTLV-I proviral DNA in oral aspirates of 
newborns born to carrier mothers"'. Perinatal infection 
of hepatitis B virus and HIV is well known. These two 
viruses transmit in cell-free manner, in contrast to the 
cell-to-cell infection of HTLV-I. Even so, the perinatal 
pathway should be evaluated as a likely candidate for 
alternative HTLV-I transmission.
 At present, refraining from breast-feeding is the 
most effective measure to break the cycle of maternal 
HTLV-I transmission in endemic areas and to prevent 
the future development of ATL. The intervention in 
Nagasaki has revealed that about 85% of maternal 
HTLV-I' transmission can be prevented by the refrain-
ing from breast-feeding by carrier mothers. If the in-
tervention will be continued, the current carrier rate 
of 4% in Nagasaki is expected to decline to 0.4% in 
the next generation, and the annual incidence of ATL, 
100, will be reduced to 10. I am reasonably confident 
that incidence of ATL in Nagasaki will decline to the 
national average level over the next few generation if 
the intervention program stays alive.
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